Previous close | 3.9900 |
Open | 4.0000 |
Bid | 4.2100 x 700 |
Ask | 4.2500 x 100 |
Day's range | 4.0000 - 4.4100 |
52-week range | 1.0700 - 4.4100 |
Volume | |
Avg. volume | 1,043,853 |
Market cap | 596.16M |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Setrusumab and Alvelestat Progress as Company Prepares for Transformative 2024